These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36534022)

  • 1. Real-world outcomes of Cook Zilver PTX in femoro-popliteal district from multicenter experience.
    Bianchini Massoni C; Strozzi F; Epifani E; Zenunaj G; Ucci A; Paladini I; Gasbarro V; Tusini N; Freyrie A
    Int Angiol; 2023 Feb; 42(1):9-18. PubMed ID: 36534022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
    Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
    Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
    Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
    J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
    Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
    J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
    [No Abstract]   [Full Text] [Related]  

  • 6. A single center experience of Zilver PTX for femoro-popliteal lesions.
    Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
    Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
    Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcome of Drug-Eluted Stenting (Zilver PTX) in Patients With Femoropopliteal Occlusive Disease a Single Center Experience.
    AbuRahma AF; Beasley M; AbuRahma ZT; Davis M; Adams E; Dean LS; Shapiro J; Scott G; Davis E
    J Endovasc Ther; 2022 Jun; 29(3):350-360. PubMed ID: 34622706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical Trial Comparing drug Eluting Stent Zilver PTX® Versus Bare Metal Stent Zilver Flex® for Treatment of Lesions in Femoral and Popliteal Arteries in Chronic Limb Threatening Ischemia.
    Fransson T; Gottsäter A; Abdulrasak M; Malina M; Resch T
    Vasc Endovascular Surg; 2023 Oct; 57(7):706-716. PubMed ID: 37085152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
    Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
    J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
    Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M
    Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
    Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
    JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
    Bosiers M; DE Donato G; Torsello G; Galvagni Silveira P; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Tessarek J; Giaquinta A; van den Eynde W; Verbist J; Wahl-Gravsen J; Bosiers MJ
    J Cardiovasc Surg (Torino); 2023 Aug; 64(4):413-421. PubMed ID: 37162238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
    Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
    Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
    Wooster M; Dansey K; Shames M
    Vasc Endovascular Surg; 2016 Feb; 50(2):80-3. PubMed ID: 26912397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents.
    Soga Y; Fujihara M; Iida O; Kawasaki D; Hirano K; Yokoi H; Miyamoto A; Kichikawa K; Nakamura M; Ohki T; Diaz-Cartelle J; Gray WA; Müller-Hülsbeck S
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):215-222. PubMed ID: 31690980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
    Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
    JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
    J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
    Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
    Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass: A paradigm shift in surgical open bypass for chronic limb-threatening ischemia.
    Kobayashi T; Hamamoto M; Okazaki T; Hasegawa M; Fujiwara T; Takahashi S
    Vascular; 2021 Dec; 29(6):905-912. PubMed ID: 33349196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.